Promotion of Research and Innovation in Pharma and MedTech Scheme

Promotion of Research and Innovation in Pharma and MedTech Scheme Latest News

Recently, the Department of Pharmaceuticals has announced the second call for applications under the Promotion of Research and Innovation in Pharma and MedTech (PRIP) Scheme. 

About Promotion of Research and Innovation in Pharma and MedTech Scheme

• It was launched to transform India into a global powerhouse for R&D in the Pharma MedTech sector.
• It is an initiative of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers in 2023.
• Total Financial Outlay: ₹5000 crores.
• The aim of the scheme is to promote industry-academia linkage for R&D in priority areas and to inculcate the culture of quality research and nurture our pool of scientists.
• Initiatives such as MedTech Mitra and Patent Mitra and the online platform under the Scheme will facilitate collaboration and partnership among various stakeholders.
• It focuses on two components
• Component A
  • Strengthening research infrastructure through establishment of Centres of Excellence (CoE) in the seven existing National Institutes of Pharmaceutical Education and Research (NIPERs). 
  • These CoEs would be set up in pre identified areas with a financial outlay of Rs 700 Crores.
• Component B
  • Promoting research in the pharmaceutical sector by encouraging research in six priority areas wherein financial assistance will be provided for the Industries, MSME, SME, Startups working with government institutes and for both in- house and academic research.
  • Under this for Early Stage Projects, MSMEs and startups may apply for projects costing up to ₹9 crore for assistance of up to ₹5 crore.
  • For Later Stage Projects, projects of industry, MSMEs and startups costing up to ₹285 crore may apply for assistance up to ₹100 crore. 
• Priority Areas
  • New Chemical Entity, New Biological Entity, and Phyto-pharmaceuticals 
  • Complex generics and Biosimilars
  • Precision medicine (Targeted innovative therapeutics)
  • Medical devices
  • Orphan Drugs 
  • Drug development for anti-microbial resistance (AMR)

Source: News On Air

‹ ›